Arnone M, Maruani J, Chaperon F, Thiébot M H, Poncelet M, Soubrié P, Le Fur G
Sanofi Recherche, Montpellier, France.
Psychopharmacology (Berl). 1997 Jul;132(1):104-6. doi: 10.1007/s002130050326.
SR 141716, a selective central CB1 cannabinoid receptor antagonist, markedly and selectively reduces sucrose feeding and drinking as well as neuropeptide Y-induced sucrose drinking in rats. SR 141716 also decreases ethanol consumption in C57BL/6 mice. In contrast, blockade of CB1 receptors only marginally affects regular chow intake or water drinking. The active doses of SR 141716 (0.3-3 mg/kg) are in the range known to antagonize the characteristic effects induced by cannabinoid receptor agonists. These results suggest for the first time that endogenous cannabinoid systems may modulate the appetitive value of sucrose and ethanol, perhaps by affecting the activity of brain reward systems.
SR 141716是一种选择性中枢CB1大麻素受体拮抗剂,能显著且选择性地减少大鼠的蔗糖摄食与饮水,以及神经肽Y诱导的蔗糖饮水行为。SR 141716还能降低C57BL/6小鼠的乙醇摄入量。相比之下,阻断CB1受 体对正常食物摄取或饮水的影响甚微。SR 141716的有效剂量(0.3 - 3毫克/千克)处于已知可拮抗大麻素受体激动剂诱导的特征性效应的范围内。这些结果首次表明,内源性大麻素系统可能通过影响脑奖赏系统的活性来调节蔗糖和乙醇的食欲价值。